Eagle Asset Management Inc. Has $78.13 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Eagle Asset Management Inc. reduced its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 8.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 621,363 shares of the company's stock after selling 58,671 shares during the quarter. Eagle Asset Management Inc. owned about 0.61% of Neurocrine Biosciences worth $78,130,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in NBIX. 1832 Asset Management L.P. increased its stake in Neurocrine Biosciences by 1,370.7% in the second quarter. 1832 Asset Management L.P. now owns 541,200 shares of the company's stock valued at $74,507,000 after acquiring an additional 504,400 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company's stock valued at $48,479,000 after purchasing an additional 363,863 shares during the last quarter. AQR Capital Management LLC increased its stake in shares of Neurocrine Biosciences by 23.0% in the 2nd quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock valued at $166,959,000 after purchasing an additional 228,444 shares during the last quarter. Iron Triangle Partners LP acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth $30,342,000. Finally, Renaissance Technologies LLC lifted its position in shares of Neurocrine Biosciences by 9.6% during the 2nd quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock worth $339,790,000 after buying an additional 216,500 shares during the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Stock Down 0.0 %

NBIX traded down $0.03 during trading on Friday, hitting $124.97. The company's stock had a trading volume of 512,232 shares, compared to its average volume of 871,384. The stock's fifty day moving average price is $118.55 and its 200-day moving average price is $132.13. The firm has a market capitalization of $12.65 billion, a P/E ratio of 33.51 and a beta of 0.35. Neurocrine Biosciences, Inc. has a twelve month low of $110.52 and a twelve month high of $157.98.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Royal Bank of Canada decreased their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research report on Friday, October 4th. Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research report on Monday, November 11th. Guggenheim increased their price objective on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. BMO Capital Markets decreased their target price on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research note on Thursday, October 17th. Finally, Robert W. Baird upped their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an "outperform" rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.